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Cardiovascular effects of an intubating dose of rocuronium 0.6 mg 
kg1 in anaesthetized patients, paralysed with vecuronium 
J. M. K. H. WIERDA, M. SCHURINGA AND L. VAN DEN BROEK 
 
Summary 
We have studied, in adult patients, ASA III, the 
cardiovascular effects of an intubating dose of 
rocuronium 0.6 mg kg1. After induction, patients 
were paralysed with vecuronium and the trachea 
intubated. Heart rate (HR) and non-invasive mean 
arterial pressure (MAP) were measured every 
1 min. After stabilization of HR and MAP, defined 
as 3% change over three measurements, rocuro- 
nium (n20) or saline (n10) was injected at 
random. Mean HR increased initially from 66.6 to 
72.1 beat min1, 4 min after rocuronium, and then 
decreased gradually to 69.6 beat min1, that is a 
net increase of 3.3 beat min1 over 10 min 
(P0.001), whereas after saline there was a 
gradual decrease from 65.8 to 60.9 beat min1 
(P0.001) over 10 min. From the third minute, HR 
was significantly higher in the rocuronium group. 
Mean MAP decreased in both groups within 10 min 
to a similar extent after rocuronium and saline, that 
is from 74.9 to 72.1 mm Hg and from 74.7 to 72.2 
mm Hg, respectively (both P0.001). There were 
no differences in MAP at any time between the 
rocuronium and saline groups. We conclude that 
an intubating dose of rocuronium, in the absence 
of haemodynamic effects related to paralysis itself, 
resulted in a limited increase in HR without change 
in MAP, probably because of its weak vagolytic 
activity. (Br. J. Anaesth. 1997; 78: 586587). 
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Rocuronium is a steroidal non-depolarizing neuro- 
muscular blocking agent with a time course similar 
to that of vecuronium, but with a faster onset of 
action. In the cat, rocuronium has a lower vagal: 
neuromuscular blocking ratio than vecuronium,1 
which may be (partly) responsible for the haemo- 
dynamic effects reported in humans.2–4 An 
indirect, relaxation-induced reduction in preload 
caused by abdominal pooling may also contribute 
to the haemodynamic effects of neuromuscular 
blocking agents. We studied the cardiovascular 
effects of an intubating dose of rocuronium in 
anaesthetized, paralysed patients, to exclude 
interference from neuromuscular block-induced 
haemodynamic effects. 
Methods and results 
After approval of the local Ethics Committee and 
with informed consent, we studied 30 ASA I–II 
patients (aged 18–65 yr), undergoing elective 
surgery. Patients with neuromuscular or cardio- 
vascular disease and those receiving any potentially 
interacting medication were excluded. After pre- 
medication with oral midazolam 0.1–0.15 mg kg1, 
anaesthesia was induced with thiopentone 4–6 mg 
kg1 i.v. and fentanyl 1–3 g kg1 i.v., and main- 
tained with 1% end- tidal isoflurane concentration 
and 65% nitrous oxide in oxygen. Tracheal intuba- 
tion was performed 3 min after vecuronium 70 g 
kg1. Heart rate (HR) and mean arterial pressure 
(MAP) were monitored non-invasively from induc- 
tion at 1-min intervals. Oxygen saturation was 
measured continuously, end-expiratory carbon 
dioxide was maintained at 4.0–4.5 kPa and neuro- 
muscular block was monitored by accelerometry 
(train-of-four ratio, TOF-Guard). After stabilization 
of HR and MAP, a bolus of rocuronium 0.6 mg kg1 
(n20) or 0.9% saline (n10) was administered 
over 10 s into a forearm vein according to a random-
ization scheme. Stability was assumed if 3% 
change in HR and MAP had occurred over the last 
three measurements. Measurements were continued 
for 10 min in the absence of surgical stimulation and 
HR and MAP were compared within each group 
(ANOVA for multiple measurements) and between 
groups (Student’s t test for independent samples). 
All patients were classified as ASA I. Groups 
(rocuronium vs control) were comparable in age 
(mean 37.5 (range 20–63) vs 34.5 (25–56) yr), 
height (mean 179 (SD 10) vs 178 (7) cm), weight 
(76.5 (10.3) vs 76.1 (10.5) kg) and sex distribution 
(M/F: 15/5 vs 6/4). The interval between intubation 
and stabilization was 12–16 min. At the time of 
administration of rocuronium or saline, all patients 
showed 95% neuromuscular block. 
HR and MAP values were similar in both groups 
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immediately before administration of rocuronium or 
saline (table 1). After rocuronium, HR increased 
significantly (P0.001), whereas after saline a 
limited, but statistically significant decrease in HR 
occurred (P0.001). In both groups MAP 
decreased with time to the same small extent 
(P0.001). After rocuronium, HR was significantly 
higher than after saline over the interval from 3 to 10 
min, whereas MAP did not differ between the 
groups (see table 1 for P values). At the end of the 
study all patients in the rocuronium group showed 
complete block whereas twitch height depression in 
the saline group was still 93.9 (4.1)%. 
Comment 
Although rocuronium has a relatively low 
vagal:neuromuscular blocking ratio in animals com- 
pared with vecuronium,1 it did not show clinically 
relevant haemodynamic effects in a dose range up to 
3ED90 in humans.3 4 Our results in paralysed 
patients are in agreement with earlier findings for the 
same dose in non-paralysed patients.3 In contrast, 
Booth and colleagues2 found more significant 
increases (30%) in HR in humans after a similar 
dose of rocuronium. However, in the latter study 
hyoscine, a vagolytic agent, which was given as pre- 
medication, may have enhanced the slight vagolytic 
effect of rocuronium, either by addition or syner- 
gism. A clinical study5 in which these drugs were 
given in reverse order may support this assumption. 
Methyl-atropine induced a more pronounced 
vagolytic effect in the presence of high concentra- 
tions of rocuronium, compared with low concentra- 
tions. In another clinical study,6 premedication with 
 
atropine i.m. was associated with a lower pre- 
induction HR, most probably because of vago- 
mimetic activity associated with small doses of 
atropine. This vagomimetic action disappeared after 
induction of anaesthesia, resulting in a more pro- 
nounced increase in HR in patients premedicated 
with atropine. These findings5 6 support the 
likelihood of a drug interaction being the explanation 
for the different increases in HR in the current study 
and in that of Booth and colleagues.2 
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Table 1 Heart rate (HR) and mean arterial pressure (MAP) just before (0 min), and for 10 min after a bolus dose of 
rocuronium 0.6 mg kg1 (2ED90) or saline (0.9% NaCl) to anaesthetized, paralysed patients. Values are mean (SD) 
and P values are for comparisons between the rocuronium and saline groups 

















  0 66.6 (11.0) 74.9 (8.2) 65.8 (10.4) 74.7 (10.3)  
  1 72.0 (11.8) 76.1 (7.5) 64.6 (9.4) 73.6 (10.4) 0.08/0.51 
  2 71.5 (11.1) 74.6 (6.9) 64.0 (9.5) 73.3 (10.8) 0.07/0.74 
  3 71.9 (11.0) 73.7 (7.9) 63.5 (9.6) 72.3 (11.0) 0.04/0.74 
  4 72.1 (10.8) 73.0 (7.3) 62.6 (9.6) 72.0 (10.6) 0.02/0.80 
  5 72.0 (10.6) 73.0 (8.0) 62.0 (9.4) 71.2 (9.8) 0.02/0.62 
  6 71.2 (10.6) 72.4 (7.3) 61.6 (8.8) 71.3 (10.8) 0.02/0.78 
  7 71.0 (10.7) 72.3 (7.6) 60.3 (8.2) 71.1 (10.4) 0.01/0.74 
  8 70.3 (10.6) 72.3 (7.4) 60.1 (8.4) 71.6 (10.0) 0.01/0.85 
  9 69.7 (10.4) 72.3 (7.1) 60.1 (7.9) 71.3 (10.6) 0.01/0.80 
10 69.6 (10.2) 72.1 (7.4) 60.9 (8.2) 72.2 (11.0) 0.02/0.97 
